Research Site
Wilmington, North Carolina, 28401, United States
Location status: Recruiting
NCT Number: NCT06659029
PRIMULA Preg (Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users) is a prospective, observational cohort study designed to evaluate the association between anifrolumab exposure during pregnancy and subsequent adverse maternal, fetal, and infant outcomes. This study will fulfil an FDA post-marketing requirement.
Interested in participating?
Request InfoFemale
Observational
Wilmington, North Carolina, 28401, United States
Location status: Recruiting
PRIMULA Preg (Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users) is a US-based, prospective, observational cohort study designed to evaluate the association between anifrolumab exposure during pregnancy and subsequent adverse maternal, fetal, and infant outcomes. The objective of the pregnancy registry is to compare adverse maternal, fetal, and infant outcomes of pregnant individuals with moderate/severe systemic lupus erythematosus (SLE) who are exposed to anifrolumab during pregnancy with outcomes in an internal comparison cohort of pregnant individuals with moderate/severe SLE who are not exposed to anifrolumab during pregnancy. Participation in the registry is voluntary and participants can withdraw their consent to participate at any time. The study is strictly observational; the schedule of office visits and all treatment regimens will be determined by HCPs. Only data that are documented in patients' medical records during medical care will be actively collected. No additional laboratory tests or HCP assessments will be required as part of this registry. This study will fulfil an FDA post-marketing requirement.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exposed cohort
Unexposed cohort
Exclusion criteria
Exposed cohort
Unexposed cohort
Anifrolumab is a human monoclonal antibody that binds to subunit 1 of the type 1 interferon receptor, which was developed based on the evidence supporting the role of type 1 interferon pathway in SLE. Clinical trial evidence from TULIP 1 and TULIP 2 have showed that monthly intravenous administration of anifrolumab led to a higher percentage of patients with a response, assessed with the British Isles Lupus Assessment Group-based Composite Lupus Assessment, compared with patients receiving placebo. Moreover, the phase II MUSE study showed that administration of anifrolumab resulted in substantially reduce disease activity, as measured by the SLE Responder Index, compared to patients receiving placebo. Anifrolumab was approved by the FDA and EMA in July 2021 and February 2022, respectively, for the treatment of adult patients with moderate to severe SLE who are receiving standard therapy.
Other names: Saphnelo
Time frame: From date of conception (DOC) to pregnancy outcome for fetal losses or 12 months of infant age for live births
An abnormality of body structure or function that is present at birth, is of prenatal origin (i.e., birth defect), has significant medical, social, or cosmetic consequences for the affected individual, and typically requires medical intervention. Relevant exposure window is limited to 1st trimester of pregnancy.
Time frame: From date of conception (DOC) to pregnancy outcome for fetal losses or 12 months of infant age for live births
An anomaly or abnormality of body structure that is present at birth, is of prenatal origin (i.e., birth defect), poses no significant health problem in the neonatal period, and tends to have limited social or cosmetic consequences for the affected individual. Relevant exposure window includes any trimester of pregnancy.
Time frame: From date of conception (DOC) to pregnancy outcome, up to 42 weeks of pregnancy
Any increase in disease activity or severity in the pregnancy period compared to the baseline period (6 months prior to pregnancy) as assessed by the disease flare or disease activity algorithms or as reported by an HCP. Relevant exposure window includes any trimester of pregnancy.
Time frame: From date of conception (DOC) to pregnancy outcome, up to 42 weeks of pregnancy
A disorder of pregnancy defined as rupture of membranes before the onset of labor. Relevant exposure window includes any trimester of pregnancy.
Time frame: From 20 gestational weeks to pregnancy outcome, up to 42 weeks of pregnancy
A disorder of pregnancy defined as a systolic blood pressure 140 mmHg or more or a diastolic blood pressure of 90 mmHg or more, or both, on 2 occasions at least 4 hours apart after 20 weeks gestation, in a woman with a previously normal blood pressure. Relevant exposure window includes any trimester of pregnancy.
Time frame: From 20 gestational weeks to pregnancy outcome, up to 42 weeks of pregnancy
Preeclampsia is a disorder of pregnancy associated with new-onset hypertension, which occurs most often after 20 weeks of gestation and frequently near term, and proteinuria. Or, in the absence of proteinuria, it is defined as new-onset hypertension with the new onset of any of the following:
Eclampsia is new-onset tonic-clonic, focal, or multifocal seizures in the absence of other causative conditions such as epilepsy, cerebral arterial ischemia and infarction, intracranial hemorrhage, or drug use.
Time frame: From date of conception (DOC) to pregnancy outcome, up to 42 weeks of pregnancy
An inpatient hospital admission unrelated to delivery occurring during pregnancy. Relevant exposure window includes any trimester of pregnancy.
Time frame: From date of conception (DOC) to <20 gestational weeks
An involuntary fetal loss or the expulsion of the products of conception occurring at <20 gestational weeks.
Time frame: From date of conception (DOC) to pregnancy outcome, up to 24 weeks of pregnancy
An intervention that is intended to terminate a suspected or known ongoing intrauterine pregnancy and that does not result in a live birth. Relevant exposure window includes any trimester of pregnancy.
Time frame: From date of conception (DOC) to pregnancy outcome, up to 42 weeks of pregnancy
A cesarean delivery that is performed due an immediate threat to the health or safety of the fetus and/or the mother. Relevant exposure window includes any trimester of pregnancy.
Time frame: From date of conception (DOC) up to 37 gestational weeks
A live birth occurring at <37 gestational weeks.
Time frame: At delivery of live birth
Birthweight <10th percentile for sex and gestational age using standard growth charts for full and preterm live-born infants. Relevant exposure window includes any trimester of pregnancy.
Time frame: At 4 and 12 months of infant age
Weight, length, or head circumference in <10th percentile for sex and chronological age using standard growth charts. Relevant exposure window includes any trimester of pregnancy.
Time frame: At 4 and 12 months of infant age
Failure to achieve the developmental milestones for chronological age, as defined by the CDC. Relevant exposure window includes any trimester of pregnancy.
Time frame: From birth to 1 year of infant age
An inpatient hospital admission occurring in the first year of life. Relevant exposure window includes any trimester of pregnancy.
Time frame: From birth to 1 year of infant age
An infection that occurs within an infant's first year of life and is either opportunistic (i.e., occurs more often or is more severe in people with weakened immune systems than in people with healthy immune systems) or serious (i.e., results in significant disability, incapacity, or death; is life-threatening; requires inpatient or prolonged hospitalization; or is considered medically important). Relevant exposure window includes any trimester of pregnancy.
Contact information is provided by the study sponsor or research team.
AstraZeneca
Industry
PRIMULA Preg (Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users): The AstraZeneca Pregnancy Study for Anifrolumab
Acronym: PRIMULA_Preg
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00001372
Autoimmune Diseases, Connective Tissue Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT00756769
Autoimmune Diseases, Connective Tissue Diseases
Charleston, South Carolina, United States
View Trial DetailsNCT07260877
Autoimmune Diseases, CLE
Beverly Hills, California, United States
View Trial DetailsNCT07598396
Autoimmune Diseases, Connective Tissue Diseases
Salvador, Estado de Bahia, Brazil
View Trial Details